Status:
UNKNOWN
The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Carcinoma, Transitional Cell
Eligibility:
All Genders
18-90 years
Brief Summary
Cysteine-rich 61 (Cyr61), a member of "CCN" family, regulates cell migration, proliferation, apoptosis, and angiogenesis, cell adhesion, migration, proliferation, survival, differentiation, apoptosis,...
Detailed Description
1. Patients: as shown in inclusion criteria 2. Surgical samples Surgical specimens from included patients with TCC who underwent surgery will be collected. The samples will be examined histologically ...
Eligibility Criteria
Inclusion
- All adult patients (age\>18 years) with TCC who received surgery at Far Eastern Memorial Hospital and National Taiwan University Hospital from 2004 to 2008.
Exclusion
- Refuse to participate.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01189838
Start Date
January 1 2010
End Date
December 1 2010
Last Update
October 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
Banqiao District, Taipei, Taiwan, 220